TDP-43 Proteinopathies: Clinical Trials

1,184 trials for TDP-43 Proteinopathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

533 completed, 214 recruiting, 148 unknown, 77 terminated. 309 Phase 2, 307 Not applicable, 195 Phase 1, 96 Phase 3, 24 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2309Completed 163, Unknown 33, Recruiting 32, Terminated 28, Active not recruiting 17, Not yet recruiting 17, Withdrawn 11, Enrolling by invitation 6, Suspended 2
Not applicable307Completed 123, Recruiting 79, Unknown 43, Active not recruiting 15, Not yet recruiting 13, Withdrawn 13, Terminated 10, Enrolling by invitation 9, Suspended 2
Phase 1195Completed 86, Recruiting 28, Unknown 22, Terminated 16, Active not recruiting 15, Not yet recruiting 15, Withdrawn 7, Enrolling by invitation 4, Suspended 2
Phase 396Completed 52, Terminated 18, Recruiting 8, Unknown 8, Active not recruiting 5, Not yet recruiting 5
Early Phase 124Completed 12, Not yet recruiting 5, Recruiting 4, Active not recruiting 1, Terminated 1, Withdrawn 1
Phase 417Completed 9, Recruiting 3, Unknown 2, Active not recruiting 1, Enrolling by invitation 1, Withdrawn 1

Follow TDP-43 Proteinopathies: new trials by email Literature Review of TDP-43 Proteinopathies trials Research Report on TDP-43 Proteinopathies

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN
Tetramethylpyrazine nitrone (TBN) tablet / Placebo - Healthy
Phase 1Not yet recruitingGuangzhou Magpie Pharmaceuticals Co., Ltd.162028-09-012026-09-11
Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS)
B cell infusion - ALS - Amyotrophic Lateral Sclerosis
Phase 1Not yet recruitingMark Poznansky102027-09-012026-09-24
iBCI Optimization for Veterans With Paralysis
Mobile neural decoding platform (mobile iBCI) - Spinal Cord Injury, Amyotrophic Lateral Sclerosis
Not applicableNot yet recruitingVA Office of Research and Development22027-04-142026-11-16
Safety Study of XT-150 in Participants With ALS
XT-150 - Amyotrophic Lateral Sclerosis (ALS)
Phase 1Not yet recruitingXalud Therapeutics, Inc.82027-03-012026-07-29
A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS)
NI112, Placebo - Amyotrophic Lateral Sclerosis (ALS)
Phase 1Not yet recruitingSachi Bioworks Inc.402027-01-222026-10-30
Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
INTENT Neural Interface System - Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS)
Not applicableRecruitingJohns Hopkins University52027-01-012026-10-09
Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)
Q-Cells - Amyotrophic Lateral Sclerosis
Phase 1 / Phase 2Not yet recruitingQ Therapeutics, Inc.302026-12-012026-07-08
Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS
nL-TARDB-002 - Amyotrophic Lateral Sclerosis (ALS)
Phase 1 / Phase 2Enrolling by invitationn-Lorem Foundation12026-12-012026-07-14
Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS
β-hydroxy-β-methylbutyrate (HMB) - Amyotrophic Lateral Sclerosis ALS
Phase 1Not yet recruitingDuke University1002026-12-012026-11-04
Brain-Computer Interface Communication Device for People With ALS
Cognixion ONE AR-BCI configuration, Cognixion ONE screen-based BCI configuration, Existing eye-gaze speech generating device - Amyotrophic Lateral Sclerosis
Not applicableRecruitingCognixion302026-11-152026-10-16
Endovascular Brain-Computer Interface for Upper-Limb Paralysis
Endovascular Venous BCI Type-A Sensor, BCI-Triggered Functional Electrical Stimulation, BCI-Controlled Bionic Robotic Arm - Stroke, Hemiplegia
Not applicableNot yet recruitingWei Wu22026-11-022026-11-13
A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum
Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD)
Not yet recruitingBioSensics602026-11-012026-10-13
Speech-Based Artificial Intelligence for Detection of Dementia in Danish Patients (DetectAI)
Mini-mental State Examination, Addenbrooke's Cognitive Examination, Speech Task - Picture Description - Dementia (Diagnosis), Alzheimer Dementia (AD)
Not yet recruitingZealand University Hospital4402026-11-012026-09-02
A Study on the Addition of Alsum30 for the Treatment of Amyotrophic Lateral Sclerosis
Sulforaphane and Bacillus coagulans GBI-30, 6086 - Amyotrophic Lateral Sclerosis (ALS), Bacillus Coagulans
Not applicableNot yet recruitingLiu Qing152026-11-012026-11-06
Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)
Orelabrutinib - Amyotrophic Lateral Sclerosis (ALS)
Phase 1Not yet recruitingLiu Qing182026-11-012026-11-06
Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis
IBM, Inclusion Body Myositis
RecruitingJohns Hopkins University302026-11-012026-10-28
REstoration of Communication and LAnguage With Intracortical Microelectrodes
RECLAIM System - Amyotrophic Lateral Sclerosis (ALS), locked-in Syndrome
Not applicableNot yet recruitingThe University of Texas Health Science Center, Houston42026-11-012026-11-12
An Early Feasibility Study of a Robotically Implanted Brain-Computer Interface for Neural Control of External Devices in Spinal Cord Injury, Amyotrophic Lateral Sclerosis, and Chronic Ischemic Stroke
N1 Implant, R1 Robot - Spinal Cord Injury, Amyotrophic Lateral Sclerosis
Not applicableRecruitingNeuralink Corp102026-11-012026-11-12
A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).
LY3873862, CYP450 Drug Cocktail, Placebo - Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
Phase 1Not yet recruitingEli Lilly and Company322026-11-012026-11-13
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies
NIO752, Placebo - Progressive Supranuclear Palsy, Corticobasal Degeneration
Phase 2Not yet recruitingNovartis Pharmaceuticals482026-10-232026-10-09

Showing 20 of 1184. Sign in to see all of them.

Narrower conditions

Amyotrophic Lateral Sclerosis (979)  ·  Frontotemporal Dementia (207)  ·  Motor Neuron Disease (146)  ·  Alzheimer Disease (128)  ·  Dementia (71)  ·  Parkinson Disease (67)  ·  Neurodegenerative Diseases (64)  ·  Lewy Body Disease (54)  ·  Frontotemporal Lobar Degeneration (47)  ·  Cognitive Dysfunction (42)  ·  Neuromuscular Diseases (40)  ·  Spinal Cord Injuries (39)  ·  Aphasia, Primary Progressive (36)  ·  Multiple Sclerosis (31)  ·  Dementia, Vascular (30)

Broader conditions

Nutritional and Metabolic Diseases (1183)  ·  Metabolic Diseases (1182)  ·  Proteostasis Deficiencies (1182)  ·  Central Nervous System Diseases (1173)  ·  Nervous System Diseases (1155)  ·  Neurodegenerative Diseases (1120)  ·  Spinal Cord Diseases (975)  ·  Neuromuscular Diseases (942)  ·  Motor Neuron Disease (834)  ·  Brain Diseases (310)  ·  Mental Disorders (270)  ·  Neurocognitive Disorders (262)  ·  Pathological Conditions, Signs and Symptoms (237)  ·  Dementia (194)

Interventions

Riluzole (24)  ·  Blood Specimen Collection (17)  ·  Spinal Puncture (11)  ·  Memantine (10)  ·  Dexpramipexole (8)  ·  Edaravone (8)  ·  Transcranial Magnetic Stimulation (8)  ·  Transcranial Direct Current Stimulation (7)  ·  sodium phenylbutyrate and taurursodiol (7)  ·  CK-2017357 (6)  ·  Magnetic Resonance Imaging (6)  ·  Noninvasive Ventilation (6)  ·  Sodium Chloride (6)  ·  Creatine (5)  ·  Observation (5)

Sponsors

Assistance Publique - Hôpitaux de Paris (24)  ·  Massachusetts General Hospital (24)  ·  Peking University Third Hospital (21)  ·  Mayo Clinic (18)  ·  Johns Hopkins University (17)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (15)  ·  University of Michigan (12)  ·  University of California, San Francisco (11)  ·  Biogen (10)  ·  Columbia University (10)  ·  Drexel University College of Medicine (10)  ·  University of Pennsylvania (10)  ·  Cytokinetics (9)  ·  Knopp Biosciences (9)  ·  Merit E. Cudkowicz, MD (9)

Countries

United States (536)  ·  France (159)  ·  Canada (113)  ·  Italy (107)  ·  Germany (83)  ·  United Kingdom (83)  ·  Netherlands (75)  ·  Spain (68)  ·  Belgium (65)  ·  China (59)  ·  Australia (49)  ·  Sweden (36)  ·  Ireland (32)  ·  Poland (31)  ·  South Korea (23)

Top investigators

Merit Cudkowicz, MD (10)  ·  Jeremy Shefner, MD, PhD (8)  ·  Bjorn Oskarsson, MD (6)  ·  Adam Boxer, MD, PhD (5)  ·  Dominic Rowe, MD (5)  ·  Dongsheng Fan (5)  ·  Merit Cudkowicz, MD, MSc (5)  ·  Terry Heiman-Patterson, MD (5)  ·  Alberto Benussi, MD (4)  ·  Benjamin R Brooks, MD (4)  ·  Hamid Gourabi, PhD (4)

Results publications

PMID 35790423, PMID 36008843, PMID 16434671, PMID 17980667, PMID 19251627, PMID 22415951, PMID 22529995, PMID 23300829, PMID 23463272, PMID 23952636, PMID 24067398, PMID 25982504, PMID 26751635, PMID 29287521, PMID 30124008, PMID 30814647, PMID 31566651, PMID 32896088, PMID 33441454, PMID 33827960, PMID 34349004, PMID 34433481, PMID 34536404, PMID 35492244, PMID 35532908, PMID 35577511, PMID 37254449, PMID 37396808, PMID 38010108, PMID 39457678, PMID 40067754, PMID 40067755, PMID 40067821, PMID 41224659, PMID 41366786, PMID 10540002, PMID 11015796, PMID 11050032, PMID 11586297, PMID 11750036, PMID 11976975, PMID 12092785, PMID 12566600, PMID 12921793, PMID 14718694, PMID 15034582, PMID 15084121, PMID 15505150, PMID 15657798, PMID 15753425

NIH funding

2023 (12), 2017 (8), 2025 (5), 2014 (3), 2015 (3), 2019 (3), R01AG055425 (3), U54NS092091 (3), 1OT2NS136938 (2), 1OT2NS136939 (2), 2016 (2), P01AG066597 (2), P01NS084974 (2), R01AG056715 (2), R01AG085029 (2)